Open access
Open access
Powered by Google Translator Translator

RCT | Cabozantinib addition to nivolumab and ipilimumab extends progression-free survival in renal-cell carcinoma

18 May, 2023 | 13:38h | UTC

Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Cabozantinib in Renal-Cell Carcinoma – NEJM Resident 360


Commentary on Twitter


Stay Updated in Your Specialty

Telegram Channels

WhatsApp alerts 10-day free trial

No spam, just news.